US 12,403,291 B2
Submucosal bioresorbable drug eluting platform
John Joseph Stankus, San Jose, CA (US); James Su, Newark, CA (US); Anthony J. Abbate, Campbell, CA (US); Tu Duc Ngo, San Jose, CA (US); Diego Javier Garnica, Sunnyvale, CA (US); and Rahul Bitla, Fremont, CA (US)
Assigned to Intersect ENT, Inc., Menlo Park, CA (US)
Filed by Intersect ENT, Inc., Menlo Park, CA (US)
Filed on Aug. 27, 2020, as Appl. No. 17/004,753.
Claims priority of provisional application 62/894,113, filed on Aug. 30, 2019.
Prior Publication US 2021/0060316 A1, Mar. 4, 2021
Int. Cl. A61M 31/00 (2006.01); A61K 9/70 (2006.01); A61K 31/58 (2006.01); A61K 47/34 (2017.01)
CPC A61M 31/00 (2013.01) [A61K 9/7007 (2013.01); A61K 31/58 (2013.01); A61K 47/34 (2013.01); A61M 2210/0618 (2013.01); A61M 2210/065 (2013.01); A61M 2210/0656 (2013.01); A61M 2210/0662 (2013.01); A61M 2210/0668 (2013.01); A61M 2210/0675 (2013.01); A61M 2210/0681 (2013.01); A61M 2210/1028 (2013.01); A61M 2210/1032 (2013.01); A61M 2210/105 (2013.01)] 26 Claims
OG exemplary drawing
 
1. A method for treating symptoms of a condition, the method comprising:
inserting a distal tip of a needle submucosally into a target tissue;
delivering a plurality of bioresorbable drug delivery platforms from the needle into the target tissue, each of the bioresorbable drug delivery platforms of the plurality of bioresorbable drug delivery platforms comprising a polymer scaffold of from about 40% to about 60% of the drug delivery platform by mass and a therapeutic agent contained within the polymer scaffold of from about 40% to about 60% of the drug delivery platform by mass, wherein a sum of the percentage by mass of the polymer scaffold and the percentage by mass of the therapeutic agent is equal to or less than 100%;
allowing the therapeutic agent to elute from each of the bioresorbable drug delivery platforms of the plurality of bioresorbable drug delivery platforms over a sustained period of time; and
allowing each of the bioresorbable drug delivery platforms of the plurality of bioresorbable drug delivery platforms to biodegrade within the target tissue,
wherein each of the bioresorbable drug delivery platforms of the plurality of bioresorbable drug delivery platforms is configured in size and mechanical integrity to pass through the needle for implantation submucosally into the target tissue, and such that the sustained period of time is from about 6 months to about 9 months,
wherein each of the bioresorbable drug delivery platforms of the plurality of bioresorbable drug delivery platforms has a biased distribution of the therapeutic agent radially out from a center of each of the bioresorbable drug delivery platforms of the plurality of bioresorbable drug delivery platforms.